Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Zhenkun Lou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1938-3091; OpenAlex author ID A5091587364; NIH RePORTER profile ID 8755021. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
33
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper, 1 grant · 2019: none · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 10

  1. Combination of PARP and KRAS G12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC. Co-author DOI 10.1038/s41467-026-69695-4↗
  2. Author Correction: Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC Co-author DOI 10.1038/s41467-026-72371-2↗
  3. Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1435↗
  4. Regulation of AMPK activation by extracellular matrix stiffness in pancreatic cancer. Co-author DOI 10.1016/j.gendis.2023.05.022↗
  5. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s43018-022-00429-3↗
  6. An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.00287↗
  7. Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.594589↗
  8. The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy. Co-author DOI 10.7150/thno.42795↗
  9. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Co-author DOI 10.1080/15384101.2017.1405194↗
  10. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Last author DOI 10.1158/0008-5472.can-15-0671↗

Grants 1

  1. The Role of WSB1 in Tumorigenesis R01CA189666↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xin Xu · 3 shared papers, 2026 · strength 0.84
  2. Changying Li · 3 shared papers, 2026 · strength 0.84
  3. Min Deng · 4 shared papers, 2016–2026 · strength 0.73
  4. Meiyu Quan · 3 shared papers, 2020 · strength 0.28
  5. Qiang Guo · 3 shared papers, 2020 · strength 0.28
  6. Jin‐San Zhang · 3 shared papers, 2020 · strength 0.28
  7. Daniel D. Billadeau · 3 shared papers, 2020 · strength 0.28
  8. Min Deng · 1 shared paper, 2026 · strength 0.26
  9. Xin Xu · 1 shared paper, 2024 · strength 0.26
  10. Min Deng · 1 shared paper, 2024 · strength 0.26
  11. Ye‐Xiong Li · 1 shared paper, 2024 · strength 0.26
  12. Yuan Fang · 1 shared paper, 2024 · strength 0.26
  13. Jiayu Liu · 2 shared papers, 2020 · strength 0.19
  14. Yu Shi · 1 shared paper, 2022 · strength 0.10
  15. Kaixiong Tao · 1 shared paper, 2022 · strength 0.10
  16. Zhijie Xu · 1 shared paper, 2022 · strength 0.10
  17. Xiangyu Zeng · 1 shared paper, 2022 · strength 0.10
  18. Xinyi Tu · 1 shared paper, 2022 · strength 0.10
  19. Wei Wang · 1 shared paper, 2020 · strength 0.09
  20. Li Ding · 1 shared paper, 2020 · strength 0.09
  21. Huijing Xu · 1 shared paper, 2020 · strength 0.09
  22. Wei Wang · 1 shared paper, 2020 · strength 0.09
  23. Jian-ang Li · 1 shared paper, 2018 · strength 0.07
  24. Yefei Rong · 1 shared paper, 2018 · strength 0.07
  25. Dansong Wang · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.